オプションチェーンは、Barksdale Resの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Barksdale Resの市場センチメントを評価します。.

Barksdale Res (OTC:BRKCF) 株価情報, オプションチェーン

Barksdale Resources Corp is a Canadian exploration-stage natural resource company. The company is principally engaged in the business activities of the acquisition and exploration of precious and base metal mineral properties. The company operates through various projects including Sunnyside, San Antonio, Canelo, Goat Canyon, San Javier, and Four Metals.

BARKSDALE RES CORP by Barksdale Resources Corp.

Barksdale Resources Corp

Needham analyst David Saxon reiterates CryoPort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYRX#NASDAQ">CYRX</a>) with a Buy and maintains $11 price target.

News

Price Target

Reiteration

Analyst Ratings

CYRX

Needham Reiterates Buy on CryoPort, Maintains $11 Price Target

Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), on Sunday, announced <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/n44552764/lillys-lepodisiran-reduced-levels-of-genetically-inherited-heart-disease-risk-factor-lipoprotein-a" rel="noreferrer noopener">positive Phase 2 results</a> for lepodisiran, an investigational small interfering RNA (siRNA) therapy designed to lower the production of lipoprotein(a) [Lp(a)], a genetically inherited risk factor for heart disease.
In the Phase 2 ALPACA study, lepodisiran significantly reduced Lp(a) levels by an average of 93.9% over the 60 to 180-day period after treatment with the highest tested dose (400 mg), meeting the primary endpoint.
Participants who received the 16 mg and 96 mg lepodisiran doses experienced a 40.8% reduction and a 75.2% reduction in Lp(a) levels over the same time period, respectively.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/03/44544761/european-drug-regulator-gives-thumbs-down-to-eli-lillys-alzheimers-drug-analyst-says-it-is-incremental-win-for-biogen" rel="noreferrer noopener">European Drug Regulator Gives Thumbs Down To Eli Lilly&#8217;s Alzheimer&#8217;s Drug, Analyst Says It Is Incremental Win For Biogen</a>
Lepodisiran also met additional secondary endpoints, showing reductions in Lp(a) levels following one or two administrations of each of the three tested doses across all timepoints assessed throughout the nearly 18-month-long study.
Results from additional secondary endpoints showed:
<ul>
<li>Participants who received 400 mg of lepodisiran at both baseline and day 180 experienced a 94.8% reduction in average Lp(a) levels over the day 30 to 360 period, which remained 91.0% below baseline at day 360 (~1 year) and 74.2% below baseline at day 540 (~1.5 years).</li>
<li>Lepodisiran also reduced apolipoprotein B (apoB) levels, a separate cholesterol biomarker.</li>
<li>The highest dose (400 mg) of lepodisiran showed 14.1% and 13.7% ApoB reductions from baseline at day 60 and 180, respectively. A second 400 mg lepodisiran dose at day 180 sustained these apoB reductions through day 540.</li>
</ul>
Treatment-emergent adverse events (TEAEs) related to the study drug occurred in 1% (1/69) of the placebo group, 3% (1/36) of the 16 mg group, 12% (9/74) of the 96 mg group, and 14% (20/141) of the pooled 400 mg group. There were no serious adverse events related to lepodisiran treatment.
A single death occurred in the 16 mg dose group due to complications of chronic coronary disease.
One participant in the placebo group was withdrawn from the study drug due to a TEAE; however, no participants receiving lepodisiran experienced a TEAE leading to withdrawal from treatment or the study.
The ACCLAIM-Lp(a) Phase 3 clinical development program, investigating the effect of lepodisiran on the reduction of cardiovascular events in adults with elevated Lp(a), is currently enrolling.
Price Action: LLY stock is down 1.42% at $810.86 at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44544107/rokus-next-chapter-analyst-sees-big-gains-from-streaming-and-ad-expansion" target="_blank" rel="noreferrer noopener">Roku&#8217;s Next Chapter: Analyst Sees Big Gains From Streaming And Ad Expansion</a></li>
</ul>
Photo via Shutterstock

Biotech

Large Cap

Health Care

General

Eli Lilly's Cholesterol Drug Reduces Genetic Heart Disease Risk Factor By 93.9%

Enovix Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENVX#NASDAQ">ENVX</a>) shares are trading lower. The company on Monday provided a progress update on its planned 2025 launch <a href="https://www.benzinga.com/pressreleases/25/03/g44560120/enovix-reports-progress-on-2025-smartphone-launch">with a smartphone OEM</a>.
What To Know: Enovix said it completed the second milestone under the development agreement it executed in October 2024 with a leading smartphone OEM, triggering a payment for shipped sample battery cells. 
Enovix noted that the samples were customized to meet specific requirements of the OEM, including cycle life, fast charge and energy density levels.
&#8220;I am pleased that our team continues to progress our most advanced smartphone agreement in-line with our aim for mass production late 2025,&#8221; said Raj Talluri, CEO of Enovix.
&#8220;Passing the ISO audit and receiving the certification was also a significant milestone, reflecting our deep commitment to quality in manufacturing operations.&#8221;
Enovix recently announced the completion of an ISO audit of Fab2 in Malaysia with no major or minor findings. The company on Monday said it received formal ISO certification last week. 
See Also: <a href="https://www.benzinga.com/economics/macro-economic-events/25/03/44560485/goldman-sachs-slashes-sp-500-price-outlook-as-tariffs-weaker-growth-hit-earnings">Goldman Sachs Slashes S&amp;P 500 Price Outlook As Tariffs, Weaker Growth Hit Earnings</a>
ENVX Price Action: <a href="http://benzinga.com/quote/envx">Enovix shares</a> were down 3.01% at $7.25 at the time of publication Monday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Shutterstock.

Movers

ENVX

Enovix Stock Is Moving Lower Monday: What's Happening?

WIIM

AIG shares are trading higher after the company announced its board authorized the repurchase of $7.5 billion worth of stock.

NEXN

Nexxen International shares are trading higher after Scotiabank initiated its coverage on the stock with a Sector Outperform rating.

HC Wainwright &amp; Co. analyst Emily Bodnar reiterates Connect Biopharma Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNTB#NASDAQ">CNTB</a>) with a Buy and maintains $8 price target.

CNTB

HC Wainwright & Co. Reiterates Buy on Connect Biopharma Hldgs, Maintains $8 Price Target

Palatin Technologies Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PTN#NYSE">PTN</a>) on Monday reported topline data with co-administered melanocortin-4 receptor (MC4R) agonist bremelanotide plus glucagon-like peptide-1/gastric inhibitory polypeptide <a target="_blank" href="https://www.benzinga.com/topic/weight-loss" rel="noreferrer noopener">(GLP-1/GIP) tirzepatide</a>.
Eli Lilly And Co&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) tirzepatide is available as Mounjaro and Zepbound for diabetes and weight loss.
Topline data results from the study were highly statistically significant for the study&#8217;s primary endpoint, which was percent weight loss in patients for the co-administration of MC4R agonist bremelanotide plus&nbsp;GLP-1/GLP tirzepatide compared to placebo, over the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/n44558732/palatin-announces-mc4r-agonist-bremelanotide-co-administered-with-glp-1gip-tirzepatide-meets-prima" rel="noreferrer noopener">8-week treatment period</a>.
<ul>
<li>The co-administered group had a 4.4% reduction in weight compared to 1.6% for the placebo group.</li>
</ul>
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44536083/palatin-technologies-touts-positive-results-from-mid-stage-study-for-experimental-drug-for-ulcerative-colitis-halts-patients-enrollment-citing-strategic-focus" rel="noreferrer noopener">Palatin Technologies Touts Positive Results From Mid-Stage Study For Experimental Drug For Ulcerative Colitis, Halts Patients Enrollment Citing Strategic Focus</a>
The primary analysis for additive effect demonstrated that:
<ul>
<li>40% of patients in the co-administered group achieved a 5% reduction in their body weight, compared to 27% for the tirzepatide alone group.</li>
<li>27% of patients in the co-administered group achieved a 6% reduction in their body weight, compared to 13% for the tirzepatide alone group.</li>
<li>19% of patients in the co-administered group achieved a 7% reduction in their body weight, compared to 0% for the tirzepatide alone group.</li>
</ul>
Over 50% of the lost weight was regained within two weeks after treatment cessation in both the co-administration and the tirzepatide-only groups, a common occurrence following the discontinuation of&nbsp;GLP-1/GIP therapy.
The data indicated that weight regain was effectively halted in the MC4R agonist bremelanotide group.
Additionally, co-administration of the MC4R agonist with the&nbsp;GLP-1/GIP therapy showed no increase in safety or tolerability concerns among patients.
Further data analysis is ongoing, including exploratory endpoints such as body composition and body mass index.
Palatin is advancing the development of its next-generation MC4R long-acting peptide and oral small molecule compounds as stand-alone treatments, as well as in combination with&nbsp;GLP-1/GIP (incretin therapy), and as monotherapy for multiple genetic obesity disorders.
Investigational New Drug applications are expected to be submitted in the fourth quarter of calendar 2025, with clinical data expected in the first half of 2026.
Price Action: PTN stock is down 14.6% at $0.5656 at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/emerging-markets/25/03/44563420/despite-us-expansion-taiwan-semiconductor-reaffirms-commitment-to-home-base-with-new-initiatives-reuters" target="_blank" rel="noreferrer noopener">Despite US Expansion, Taiwan Semiconductor Reaffirms Commitment To Home Base With New Initiatives: Reuters</a></li>
</ul>
Photo via Shutterstock.

Equities

Palatin Technologies' Obesity Drug Co-Administered With Eli Lilly's Blockbuster Drug Shows 4.4% Reduction In Weight

Raymond James analyst C. Gregory Peters maintains The Hartford Insurance Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIG#NYSE">HIG</a>) with a Outperform and raises the price target from $125 to $135.

Raymond James Maintains Outperform on The Hartford Insurance Gr, Raises Price Target to $135

Dividends

TJX Companies Raises Dividend From $0.38 To $0.425/Share

AuthID Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUID#NASDAQ">AUID</a>) shares are trading lower by 26.6% to $4.75 during Monday&#8217;s session after the company announced an <a href="https://www.benzinga.com/pressreleases/25/03/g44560119/authid-announces-pricing-of-approximately-8-150-000-million-registered-direct-offering">$8.15 million offering</a>.
What To Know: Denver-based biometric authentication firm AuthID has announced a registered direct offering, raising approximately $8.15 million through the sale of 1.81 million shares and pre-funded warrants at $4.50 each. The offering is expected to close by April 1.
AuthID is also forming an Advisory Board, featuring Eric Swider, CEO of Rubidex, and Donald Nitti, Founder of Chroma Ventures. Swider, a former DWAC CEO, praised authID's biometric authentication technology, while Nitti highlighted its potential across various industries.
CEO Rhon Daguro emphasized authID's commitment to combating fraud and deepfake threats. The proceeds from the offering will support working capital and corporate expansion.
Read Also: <a href="https://www.benzinga.com/economics/macro-economic-events/25/03/44560485/goldman-sachs-slashes-sp-500-price-outlook-as-tariffs-weaker-growth-hit-earnings">Goldman Sachs Slashes S&amp;P 500 Price Outlook As Tariffs, Weaker Growth Hit Earnings</a>
<h2 class="wp-block-heading">How To Buy AUID Stock</h2>
By now you're likely curious about how to participate in the market for AuthID &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy &#8220;fractional shares,&#8221; which allows you to own portions of stock without buying an entire share.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to &#8220;go short&#8221; a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, AUID has a 52-week high of $12.31 and a 52-week low of $4.01.

AUID

Why AuthID Shares Are Down More Than 25%

Raymond James analyst John Freeman maintains Range Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RRC#NYSE">RRC</a>) with a Outperform and raises the price target from $46 to $55.

Raymond James Maintains Outperform on Range Resources, Raises Price Target to $55

Raymond James analyst Brian MacArthur maintains Barrick Gold (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GOLD#NYSE">GOLD</a>) with a Outperform and raises the price target from $23 to $23.5.

GOLD

Raymond James Maintains Outperform on Barrick Gold, Raises Price Target to $23.5

In a recent <a href="https://x.com/GrantCardone/status/1905388366050238952">post</a> on X, entrepreneur and real estate investor Grant Cardone fired off a direct message to critics of Elon Musk and his government agency, DOGE: &#8220;You guys opposing DOGE actually ARE NOT GOOD Americans.&#8221;
Cardone backed up his statement with a quote from Musk: &#8220;The sheer amount of waste and fraud in the government, it is astonishing — it&#8217;s mind-blowing. We routinely encounter wastes of $1 billion or more — casually.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">You guys opposing DOGE actually ARE NOT GOOD Americans. "The sheer amount of waste and fraud in the government, it is astonishing — it's mind boggling. We routinely encounter wastes of $1 billion or more — casually." Elon Musk <a href="https://t.co/vCxc5fgKm8">pic.twitter.com/vCxc5fgKm8</a>
&mdash; Grant Cardone (@GrantCardone) <a href="https://twitter.com/GrantCardone/status/1905388366050238952?ref_src=twsrc%5Etfw">March 27, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Don't Miss:
<ul>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a></li>
<li><a href="https://www.benzinga.com/money/startengine-own">The $1.3 billion startup investment boom: How this company's explosive growth is opening doors for everyday investors with a new $500 minimum</a></li>
</ul>
<h2 class="wp-block-heading">Musk Says DOGE is Saving the U.S. Billions</h2>
The comment comes on the heels of a wide-ranging Fox News <a href="https://www.youtube.com/watch?v=l7kQNwJ4H_w">interview</a> with Musk and his DOGE team, where they laid out the scope of government waste and what they're doing to stop it.
DOGE's goal is apparently to <a href="https://www.benzinga.com/startups/25/01/43046108/musks-doge-ambitions-shrink-why-2-trillion-budget-cuts-may-be-out-of-reach">cut the federal deficit by $1 trillion</a>. Musk said that means dropping the annual deficit from $2 trillion to $1 trillion and cutting federal spending from $7 trillion to $6 trillion by rooting out fraud and waste.
&#8220;We feel confident that a 15% reduction can be done without affecting any of the critical government services,&#8221; Musk said.
He shared a stunning example: a simple 10-question online survey about national parks, which could have been done with SurveyMonkey for $10,000. &#8220;The government was being charged almost a billion dollars for that,&#8221; he claimed. &#8220;A billion dollars for a simple online survey—Do you like the national park?&#8221;
Trending: Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">invest pre-IPO from $0.55 per share now</a>.
<h2 class="wp-block-heading">Social Security, Medicare and What's Not Being Cut</h2>
Musk and the DOGE team pushed back hard against allegations that they're trying to cut Social Security or Medicare.
&#8220;Legitimate recipients of Social Security will receive more money, not less money,&#8221; Musk said. &#8220;Let the record show that I said this.&#8221;
The team said they are protecting benefits by cutting off fraud and fixing broken systems. They cited phone scams where 40% of Social Security calls are from fraud centers trying to reroute benefits.
See Also: This platform is reshaping how you invest in private companies —<a href="https://www.benzinga.com/money/kingscrowd-adv"> and you can be a part of it for $0.18 per share</a>
<h2 class="wp-block-heading">Cuban Pushes Back: Government Isn't a Business</h2>
Not everyone is applauding DOGE's aggressive cuts. Billionaire investor Mark Cuban recently <a href="https://www.benzinga.com/personal-finance/25/03/44484549/mark-cuban-on-doge-government-cuts-this-isnt-a-corporate-turnaround-this-is-the-united-states-of-america">warned that rushing to slash government programs</a> could cause more harm than good.
&#8220;I am all for cutting gov costs, then and now. I'm even more for efficiency,&#8221; Cuban <a href="https://x.com/realchrisrufo/status/1902787469625659629">wrote</a> on X. &#8220;I would have a plan. Ready Fire Aim is not a plan.&#8221;
He stressed that many cities rely heavily on federal jobs, and sudden mass layoffs could damage local economies, housing markets and essential services. &#8220;How many people will lose their jobs and homes because this was done ALL AT ONCE?&#8221; Cuban asked.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/money/vatom-adv">Invest in the Future of Digital Engagement. Own a Piece of the $100 Billion Metaverse Today for Just $500.</a></li>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.26/share with a $1000 minimum.</a></li>
</ul>

You're Not A Good American If You're Against DOGE, Says Grant Cardone, Slamming Critics Of Musk And His Agency

Johnson Controls Intl's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JCI#NYSE">JCI</a>) short percent of float has fallen 4.55% since its last report. The company recently reported that it has 9.47 million shares sold short, which is 1.89% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.84 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Johnson Controls Intl Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743438627_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Johnson Controls Intl has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Johnson Controls Intl's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Johnson Controls Intl's peer group average for short interest as a percentage of float is 4.29%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

Looking Into Johnson Controls Intl's Recent Short Interest

Nutanix's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NTNX#NYSE">NTNX</a>) short percent of float has fallen 12.57% since its last report. The company recently reported that it has 7.50 million shares sold short, which is 3.27% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.17 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Nutanix Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743438622_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Nutanix has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Nutanix's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Nutanix's peer group average for short interest as a percentage of float is 3.06%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

NTNX

How Do Investors Really Feel About Nutanix?

Bright Horizons Family's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BFAM#NYSE">BFAM</a>) short percent of float has risen 37.06% since its last report. The company recently reported that it has 1.18 million shares sold short, which is 2.33% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.77 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Bright Horizons Family Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743438617_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Bright Horizons Family has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Bright Horizons Family's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Bright Horizons Family's peer group average for short interest as a percentage of float is 4.16%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

BFAM

Is the Market Bullish or Bearish on Bright Horizons Family?

HC Wainwright &amp; Co. analyst Edward White maintains Curis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRIS#NASDAQ">CRIS</a>) with a Buy and lowers the price target from $20 to $16.

CRIS

HC Wainwright & Co. Maintains Buy on Curis, Lowers Price Target to $16

BlackRock (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLK#NYSE">BLK</a>) CEO Larry Fink raised serious concerns about the long-term health of the U.S. economy, warning that unchecked national debt and growing fiscal deficits could undermine the dollar's dominance as the <a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44499889/bitcoin-is-fulfilling-its-destiny-as-world-reserve-currency-says-bitcoin-whale-trace-mayer">world's reserve currency</a>.
What Happened: In his annual letter to shareholders <a href="https://www.blackrock.com/corporate/literature/presentation/larry-fink-annual-chairmans-letter.pdf">released</a> on Monday, he cautioned that <a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44560290/trump-family-to-dive-into-bitcoin-mining-after-defi-meme-coin-projects">digital assets like Bitcoin</a> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) may emerge as a viable alternative if the government fails to rein in spending.
"The dollar's position as the global reserve currency is not guaranteed," Fink wrote. 
He pointed to a troubling trend: since 1989, when the national debt clock first went up in Times Square, U.S. debt has expanded at triple the rate of economic growth. 
He projected that interest payments on government debt will exceed $952 billion this year, surpassing defense spending for the first time.
If this trajectory isn't corrected, Fink warned that by the end of the decade, every dollar of federal revenue will be consumed by mandatory spending and debt service—pushing the nation into a state of perpetual deficit.
While acknowledging the disruptive potential of decentralized finance, Fink cautioned that digital innovation could weaken America's economic standing if Bitcoin begins to be seen as a safer store of value than the dollar. 
"I'm not against digital assets," he noted.
"Decentralized finance is transformative—making markets more efficient and transparent—but it could also threaten U.S. financial supremacy."
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44558783/mara-holdings-joins-gamestop-metaplanet-in-bitcoin-reserve-push-with-2-billion-stock-sale">MARA Holdings Joins GameStop, Metaplanet In Bitcoin Reserve Push With $2 Billion Stock Sale</a>
Highlighting BlackRock's growing crypto footprint, Fink spotlighted the success of its <a href="https://www.benzinga.com/money/best-spot-bitcoin-etfs">U.S. spot Bitcoin ETF</a>, (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBIT#NASDAQ">IBIT</a>), which has become the largest ETF debut in history.
Since its launch, IBIT has grown to more than $50 billion in assets under management, attracting $37.4 billion in net inflows during 2024 alone.
This puts it far ahead of rivals like Fidelity's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FBTC#NASDAQ">FBTC</a>), which has drawn $11.5 billion to date, according to data from The Block.
IBIT has also emerged as the third-largest asset gatherer across the <a href="https://in.benzinga.com/markets/cryptocurrency/25/03/44359400/bitcoin-etfs-see-record-5-5-billion-in-outflows-in-5-weeks-as-tariff-turbulence-looms">entire ETF industry</a>—trailing only behind the dominant S&amp;P 500 funds.
Notably, over half its demand came from retail investors, and three-quarters of those investing had never previously bought an iShares product, indicating a broadening investor base. 
BlackRock has since extended its Bitcoin investment offerings to markets in Canada and Europe.
Fink also revisited an earlier estimate he made, suggesting that if global investors began allocating 2% to 5% of their portfolios to Bitcoin, its price could someday reach $700,000.
What&#8217;s Next: Looking beyond Bitcoin, Fink emphasized the transformative <a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44456074/tokenization-will-merge-crypto-and-equities-bernstein">power of tokenization</a>—turning real-world assets like bonds, real estate, or equities into digital tokens tradable on a blockchain.
He likened the shift to the leap from postal services to email, suggesting this technological leap could fundamentally change how financial markets operate.
"Every asset can be tokenized," Fink said. "If that happens, investing will be revolutionized. Markets would never need to close. Settlements would be instantaneous. And trillions tied up in clearing delays could be put back to work immediately, accelerating economic growth."
He argued that tokenization has the potential to make investing more inclusive by enabling fractional ownership, faster shareholder voting, and broader access to high-yield assets—benefiting everyday investors, not just the ultra-wealthy.
Fink concluded his letter by reflecting on the role of financial markets in promoting global prosperity. 
While he acknowledged the current economic uncertainty, he reminded investors that history shows resilience often prevails. 
"Periods of doubt are nothing new," he wrote. "But like before, innovation and human adaptability will drive long-term economic stability."
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44543709/peter-schiff-tells-bitcoin-hodlers-to-get-a-clue-as-gold-outpaces-digital-gold">Peter Schiff Tells Bitcoin &#8216;Hodlers&#8217; To &#8216;Get A Clue&#8217; As Gold Outpaces Digital Gold</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

Fidelity Wise Origin Bitcoin Fund Fidelity Wise Origin Bitcoin Fund

FBTC

IBIT

BlackRock CEO Larry Fink Says Bitcoin Can Rival Dollar As Global Reserve Currency

HC Wainwright &amp; Co. analyst Joseph Pantginis maintains BioLine Rx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLRX#NASDAQ">BLRX</a>) with a Buy and raises the price target from $9 to $26.

Comments

Barksdale Res

Barksdale Res (BRKCF) オプション

No option chain data available. Please try again later

ニュース

パートナーシップ

ベンジンガ・グローバル